Literature DB >> 28545934

Cure modeling in real-time prediction: How much does it help?

Gui-Shuang Ying1, Qiang Zhang2, Yu Lan3, Yimei Li4, Daniel F Heitjan5.   

Abstract

Various parametric and nonparametric modeling approaches exist for real-time prediction in time-to-event clinical trials. Recently, Chen (2016 BMC Biomedical Research Methodology 16) proposed a prediction method based on parametric cure-mixture modeling, intending to cover those situations where it appears that a non-negligible fraction of subjects is cured. In this article we apply a Weibull cure-mixture model to create predictions, demonstrating the approach in RTOG 0129, a randomized trial in head-and-neck cancer. We compare the ultimate realized data in RTOG 0129 to interim predictions from a Weibull cure-mixture model, a standard Weibull model without a cure component, and a nonparametric model based on the Bayesian bootstrap. The standard Weibull model predicted that events would occur earlier than the Weibull cure-mixture model, but the difference was unremarkable until late in the trial when evidence for a cure became clear. Nonparametric predictions often gave undefined predictions or infinite prediction intervals, particularly at early stages of the trial. Simulations suggest that cure modeling can yield better-calibrated prediction intervals when there is a cured component, or the appearance of a cured component, but at a substantial cost in the average width of the intervals.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bayesian bootstrap; Enrollment model; Event-based trial; Interim analysis; Weibull distribution

Mesh:

Year:  2017        PMID: 28545934      PMCID: PMC5571982          DOI: 10.1016/j.cct.2017.05.012

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  26 in total

1.  Estimation in a Cox proportional hazards cure model.

Authors:  J P Sy; J M Taylor
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

Review 2.  Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.

Authors:  Xiaoxi Zhang; Qi Long
Journal:  Clin Trials       Date:  2012-06-06       Impact factor: 2.486

3.  Weibull prediction of event times in clinical trials.

Authors:  Gui-shuang Ying; Daniel F Heitjan
Journal:  Pharm Stat       Date:  2008 Apr-Jun       Impact factor: 1.894

4.  A hybrid approach to predicting events in clinical trials with time-to-event outcomes.

Authors:  Liang Fang; Zheng Su
Journal:  Contemp Clin Trials       Date:  2011-05-30       Impact factor: 2.226

Review 5.  Real-time prediction of clinical trial enrollment and event counts: A review.

Authors:  Daniel F Heitjan; Zhiyun Ge; Gui-Shuang Ying
Journal:  Contemp Clin Trials       Date:  2015-07-16       Impact factor: 2.226

6.  The use of mixture models for the analysis of survival data with long-term survivors.

Authors:  V T Farewell
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Authors:  J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

8.  Prediction of accrual closure date in multi-center clinical trials with discrete-time Poisson process models.

Authors:  Gong Tang; Yuan Kong; Chung-Chou Ho Chang; Lan Kong; Joseph P Costantino
Journal:  Pharm Stat       Date:  2012-03-12       Impact factor: 1.894

9.  Probabilistic prediction in patient management and clinical trials.

Authors:  D J Spiegelhalter
Journal:  Stat Med       Date:  1986 Sep-Oct       Impact factor: 2.373

Review 10.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

View more
  2 in total

1.  BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint.

Authors:  Beibei Guo; Yong Zang
Journal:  Stat Med       Date:  2021-11-25       Impact factor: 2.497

2.  Factors Affecting Long-Survival of Patients with Breast Cancer by Non-Mixture and Mixture Cure Models Using the Weibull, Log-logistic and Dagum Distributions: A Bayesian Approach.

Authors:  Shideh Rafati; Mohammad Reza Baneshi; Abbas Bahrampour
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.